Tools

LEADER 03060nam 22004212 4500

001 ssj0003417702;

003 WaSeSS;

005 20250812090346.0;

006 m d ;

007 cr n ;

008 040206e200405uumou s|||||||| 2|eng|d;

020 a| 9780444511430;

020 a| 0444511431 (Trade Cloth)c| USD 209.00 Retail Price9| Active Record;

024 3 a| 9780444511430;

035 a| (WaSeSS)ssj0003417702;

037 b| 00008838;

040 a| BIP USd| WaSeSS;

049 a| EREEa| NEHH;

082 00 a| 615.192| 22;

100 1 a| King, F. D.e| Author?| UNAUTHORIZED;

245 10 a| Progress in Medicinal Chemistry.n| Vol. 42h| [electronic resource];

260 a| New York : b| Elsevier;

300 a| 410 p.c| 22.000 x 015.000 cm.;

506 a| Available only to authorized users.;

520 8 a| Annotationb| The complex and multidisciplinary nature of modern drug discovery is well illustrated in the six chapters of this volume that describe exciting developments in both newly emerging and mature areas of medicinal chemistry. Chapter 1 provides a comprehensive review of therapeutic applications of ligands for peroxisome proliferator-activated receptor gamma PPAR?, a key regulator of glucose and lipid homeostasis. Progress over the last decade on ligands that bind to central nicotinic acetylcholine receptors is timely reviewed in Chapter 2, with the emphasis on the a4ß2 subtype. Chapter 3 reviews inhibitors of PARP-1, the founding member of the family, with the focus on their therapeutic potential in ischaemia related CNS injuries. Chapter 4 describes the structure-activity relationships of some semi-synthetic analogues including promising new compounds in development. Chapter 5 describes selective, first generation, non-peptidic neuropeptide Y1 and Y2 antagonists and their actions and evaluates their potential therapeutic application in cardiovascular disorders, with the emphasis on NPY1 antagonists. Chapter 6 is an extensive review of the considerable progress that has been achieved in developing Cathepsin K inhibitors and evaluates their potential for treating arthritis and atherosclerosis.;

538 a| Mode of access: World Wide Web;

650 4 a| Pharmaceutical Chemistry;

655 0 a| Electronic books.=| ^A491897;

856 40 z| Full text available from Book Series Package - Life Sciences [BSLFSC]u| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Fbookseries%2F00796468%2F42;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 6609103;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6609103-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 8/14/2025x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6609103-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 8/14/2025x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6609103-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 8/14/2025x| EBOOKz| JERESOURCE;

Progress in Medicinal Chemistry.

Author/creator	King, F. D. Author
Format	Electronic
Publication Info	New York : Elsevier
Description	410 p. 22.000 x 015.000 cm.
Supplemental Content	Full text available from Book Series Package - Life Sciences [BSLFSC]
Subjects	Pharmaceutical Chemistry

Summary	Annotation The complex and multidisciplinary nature of modern drug discovery is well illustrated in the six chapters of this volume that describe exciting developments in both newly emerging and mature areas of medicinal chemistry. Chapter 1 provides a comprehensive review of therapeutic applications of ligands for peroxisome proliferator-activated receptor gamma PPAR?, a key regulator of glucose and lipid homeostasis. Progress over the last decade on ligands that bind to central nicotinic acetylcholine receptors is timely reviewed in Chapter 2, with the emphasis on the a4ß2 subtype. Chapter 3 reviews inhibitors of PARP-1, the founding member of the family, with the focus on their therapeutic potential in ischaemia related CNS injuries. Chapter 4 describes the structure-activity relationships of some semi-synthetic analogues including promising new compounds in development. Chapter 5 describes selective, first generation, non-peptidic neuropeptide Y1 and Y2 antagonists and their actions and evaluates their potential therapeutic application in cardiovascular disorders, with the emphasis on NPY1 antagonists. Chapter 6 is an extensive review of the considerable progress that has been achieved in developing Cathepsin K inhibitors and evaluates their potential for treating arthritis and atherosclerosis.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
ISBN	9780444511430
ISBN	0444511431 (Trade Cloth) Active Record
Standard identifier#	9780444511430
Stock number	00008838

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Progress in Medicinal Chemistry.

Click here for more information about this title

Availability